Form 4: Vertex Pharmaceuticals Executive Tatsis Reports Stock Transactions
SEC Form 4 Filing
Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals, reports the disposition and acquisition of company stock.
Summary
- On February 24, 2025, Ourania Tatsis disposed of 3,310 shares of Vertex Pharmaceuticals common stock to cover tax obligations at a price of $483.28 per share.
- On February 25, 2025, Tatsis sold 354 shares of common stock at a price of $480.95 per share.
- Following these transactions, Tatsis directly owns 64,031 shares of Vertex Pharmaceuticals common stock.
- The transactions were executed under a pre-arranged trading plan (Rule 10b5-1) established on February 29, 2024.
Sentiment
Score: 5
Explanation: The document is a neutral report of stock transactions by an executive, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is a common occurrence in the pharmaceutical industry. Investors often monitor these filings for insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 02/29/2024 | Date of entry into Rule 10b5-1 trading plan |
| 02/24/2025 | Disposition of 3,310 shares for tax obligations |
| 02/25/2025 | Sale of 354 shares |
| 02/26/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.